Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)
Egypt · Delayed Price · Currency is EGP 5.68
+0.05 (0.89%)
At close: Nov 12, 2026
EGX:RMDA Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,403 | 4,096 | 2,769 | 1,922 | 1,484 | 1,246 | |
Revenue Growth | 11.52% | 47.94% | 44.03% | 29.54% | 19.06% | 29.81% |
Cost of Revenue | 2,157 | 2,114 | 1,485 | 1,018 | 765.28 | 669.61 |
Gross Profit | 2,246 | 1,982 | 1,284 | 904.06 | 718.67 | 576.82 |
Selling, General & Admin | 1,080 | 907.93 | 558.11 | 444.06 | 360.96 | 303.18 |
Other Operating Expenses | -3.3 | -8.98 | -27.3 | -7.34 | -6.04 | -0.76 |
Operating Expenses | 1,227 | 1,020 | 558.54 | 458.3 | 376.41 | 302.53 |
Operating Income | 1,019 | 962.45 | 725.44 | 445.76 | 342.26 | 274.29 |
Interest Expense | -504.73 | -531.27 | -307.21 | -191.2 | -89.07 | -91.03 |
Interest & Investment Income | 0.92 | 18.81 | 65.85 | 62.9 | 56.73 | 59.97 |
Currency Exchange Gain (Loss) | 5.94 | -6.14 | 56.24 | 18.68 | 25.65 | -0.6 |
Other Non Operating Income (Expenses) | -20.38 | -17.34 | -11.7 | -8.84 | -6.99 | -8.31 |
EBT Excluding Unusual Items | 500.94 | 426.51 | 528.62 | 327.31 | 328.58 | 234.33 |
Gain (Loss) on Sale of Assets | 0.01 | 0.15 | 0.01 | 0.14 | -0.13 | -0.72 |
Asset Writedown | -2.56 | -2.56 | -2.51 | - | - | - |
Pretax Income | 498.4 | 424.1 | 526.12 | 327.45 | 328.45 | 233.61 |
Income Tax Expense | 130.29 | 110.89 | 124.31 | 74.24 | 75.57 | 53.52 |
Earnings From Continuing Operations | 368.11 | 313.21 | 401.81 | 253.21 | 252.89 | 180.09 |
Minority Interest in Earnings | 2.47 | -14.75 | -14.44 | -8.35 | -7.21 | 1 |
Net Income | 370.58 | 298.46 | 387.37 | 244.86 | 245.68 | 181.09 |
Preferred Dividends & Other Adjustments | 29.85 | 29.85 | 23.53 | 21.36 | 16.76 | 14.7 |
Net Income to Common | 340.73 | 268.61 | 363.84 | 223.5 | 228.91 | 166.39 |
Net Income Growth | -14.31% | -26.17% | 62.80% | -2.37% | 37.58% | 70.69% |
Shares Outstanding (Basic) | 2,010 | 2,000 | 2,002 | 1,973 | 1,952 | 2,015 |
Shares Outstanding (Diluted) | 2,020 | 2,010 | 2,009 | 1,987 | 1,962 | 2,015 |
Shares Change | -0.07% | 0.02% | 1.11% | 1.27% | -2.62% | - |
EPS (Basic) | 0.17 | 0.13 | 0.18 | 0.11 | 0.12 | 0.08 |
EPS (Diluted) | 0.17 | 0.13 | 0.18 | 0.11 | 0.12 | 0.08 |
EPS Growth | -14.23% | -26.23% | 60.98% | -3.52% | 41.22% | 70.69% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 93.93 | -199.57 | -371.85 | -135.54 | -5.03 | 188.68 |
Free Cash Flow Per Share | 0.05 | -0.10 | -0.18 | -0.07 | -0.00 | 0.09 |
Dividend Per Share | - | - | 0.040 | 0.051 | - | - |
Dividend Growth | - | - | -20.71% | - | - | - |
Gross Margin | 51.01% | 48.39% | 46.38% | 47.03% | 48.43% | 46.28% |
Operating Margin | 23.15% | 23.50% | 26.20% | 23.19% | 23.06% | 22.01% |
Profit Margin | 7.74% | 6.56% | 13.14% | 11.63% | 15.43% | 13.35% |
Free Cash Flow Margin | 2.13% | -4.87% | -13.43% | -7.05% | -0.34% | 15.14% |
EBITDA | 1,099 | 1,046 | 804.84 | 514.61 | 403.67 | 316.61 |
EBITDA Margin | 24.96% | 25.53% | 29.07% | 26.77% | 27.20% | 25.40% |
D&A For EBITDA | 79.88 | 83.39 | 79.4 | 68.85 | 61.41 | 42.31 |
EBIT | 1,019 | 962.45 | 725.44 | 445.76 | 342.26 | 274.29 |
EBIT Margin | 23.15% | 23.50% | 26.20% | 23.19% | 23.06% | 22.01% |
Effective Tax Rate | 26.14% | 26.15% | 23.63% | 22.67% | 23.01% | 22.91% |